Sweden Bio interview with CEO Kristina Torfgård

The FDA granted an accelerated approval for aducanumab on June 7, 2021. The decision to approve a new treatment for Alzheimer’s disease in the USA creates opportunities for Swedish life science companies. Sweden Bio interviewed our CEO Kristina Torfgård about what the announcement means.